Sandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts...
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on...
View ArticleNovartis division Sandoz receives US FDA complete response letter regarding...
Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the...
View ArticleSandoz announces European Commission approval for Zessly® (infliximab) for...
European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier...
View ArticleClik here to view.
Global generics industry newsletter Generics Bulletin awarded “Biosimilars...
Holzkirchen, 16-10-2014 — /EuropaWire/ — Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded...
View ArticleSandoz announced Phase III data that demonstrated similarity of its...
Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the...
View ArticleSandoz: 160,000 – 200,000 children estimated to be diagnosed with childhood...
Holzkirchen, Germany, 6-2-2015 — /EuropaWire/ — Between 160,000 and 200,000 children are estimated to be diagnosed with childhood cancer and around 100,000 die from it each year. With proper diagnosis,...
View ArticleClik here to view.
Sandoz launches New Life & New Hope program aimed at improving maternal and...
Approximately 400 mothers and newborns die in Ethiopia each day1,2partly due to health workers’ limited knowledge in the area of obstetrics Enhancing medical knowledge and skills of health workers...
View ArticleSandoz launches respiratory health program aimed at improving the diagnosis...
Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is ranked #1 in the world for mortality due to asthma2...
View ArticleSandoz announced US market introduction of its generic version of Pulmicort...
Princeton, New Jersey, 30-7-2015 — /EuropaWire/ — Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide)...
View ArticleSandoz continues to advance its biosimilars program: US FDA acceptance for...
Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking...
View ArticleSandoz and World Child Cancer announce new health initiative in the Philippines
Holzkirchen, Germany, 18-Feb-2016 — /EuropaWire/ — Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at...
View ArticleEuropean Medicines Agency accepted Sandoz’s Marketing Authorization...
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product’s label Sandoz’...
View ArticleSandoz’s EGALITY trial results: equivalence in Psoriasis Area and Severity...
The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the confirmatory...
View ArticleNew Sandoz Biosimilar Shows Promising Equivalency Results
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®* Comprehensive development program show potential of GP2017...
View ArticleNovartis Reinforces Commitment to Sandoz With Major Investment in Business
Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic...
View ArticleSandoz: European Commission approves Rixathon for use in Europe
European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare...
View ArticleGeneric medicines accounted for 62% of all medicines prescribed in Europe in...
New data just released in the two largest global pharma markets show the substantial and growing level of savings made possible by increased use of generic medicines. HOLZKIRCHEN, 21-Jun-2017 —...
View ArticleClik here to view.
Sandoz today expands pilot project with leading charity World Child Cancer
Bon Bon is being treated by Doc Mae and her team at the Southern Philippines Medical Center. Expanded partnership to help “even the odds” of survival for children with cancer in the Philippines,...
View ArticleSandoz certified “TOP Employer Asia Pacific 2019” for its exceptional...
Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute...
View ArticleClik here to view.
Francesco Balestrieri appointed ad-interim CEO of Sandoz reporting directly...
Francesco Balestrieri appointed ad-interim CEO of Sandoz BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz’s current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO of Sandoz...
View Article
